Safety of Aerius Syrup in Pediatric Patients Aged 1-5 Years Old With Allergic Rhinitis or Chronic Idiopathic Urticaria (Study P04446AM1)(COMPLETED)

Organon and Co100 enrolled

Overview

The objective of this non-interventional study is to evaluate the safety of Aerius syrup in pediatric patients aged 1-5 years old with allergic rhinitis or chronic idiopathic uticaria. The patients will receive 2.5 ml (1.25 mg) once daily.

Pediatric patients aged 1-5 years

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Rhinitis Urticaria

Interventions

DesloratadineDRUG

2.5 ml (1.25 mg) once daily

Eligibility

Sex: ALLMin age: 1 YearMax age: 5 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with allergic rhinitis or chronic idiopathic urticaria * Aged 1-5 years old * Caregiver's consent to participate Exclusion Criteria: * Healthy individuals * Younger or older than the 1-5 year old age range

Outcomes

Primary Outcomes

Proportion of Patients With Adverse Events

An adverse event is any untoward medical occurrence or unfavorable and unintended sign in a subject administered a pharmaceutical product, whether or not considered related to the use of that product. This includes the onset of new illness and the exacerbation of pre-existing conditions.

Time frame: Follow-up visit at 3 - 5 weeks after treatment initiation

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.